Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 925 INR 0.54%
Market Cap: 930.8B INR

Zydus Lifesciences Ltd
Deferred Income Tax

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Zydus Lifesciences Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Deferred Income Tax
₹16.4B
CAGR 3-Years
134%
CAGR 5-Years
54%
CAGR 10-Years
41%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Deferred Income Tax
₹14.8B
CAGR 3-Years
874%
CAGR 5-Years
258%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Deferred Income Tax
₹416.8m
CAGR 3-Years
-37%
CAGR 5-Years
-33%
CAGR 10-Years
-20%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Deferred Income Tax
₹3.9B
CAGR 3-Years
130%
CAGR 5-Years
55%
CAGR 10-Years
22%
Lupin Ltd
NSE:LUPIN
Deferred Income Tax
₹2.3B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
1%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Deferred Income Tax
₹7.9B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
11%
No Stocks Found

Zydus Lifesciences Ltd
Glance View

Zydus Lifesciences Ltd., a resilient player in India's pharmaceutical industry, traces its origins back to 1952, when it was founded in Ahmedabad. Over the decades, it has metamorphosed from a modest venture into a global healthcare presence, with a diverse repertoire that spans across pharmaceuticals, animal health, and consumer wellness products. The company's ethos is deeply embedded in innovation, steadfastly pursuing research and development to propel its pipeline of generics, novel therapeutics, and vaccines. With a robust manufacturing infrastructure spread across continents, Zydus ensures seamless distribution and availability of its products, thereby maintaining a key foothold in both established and emerging markets. The lifeblood of Zydus's profitability streams from its comprehensive product portfolio, catering to a myriad of therapeutic areas such as cardiology, gastroenterology, and women's health, among others. It generates revenue primarily through the sale of branded generics and active pharmaceutical ingredients (APIs). Strategic alliances and collaborations further bolster its growth trajectory, providing new avenues for market expansion and technological advancements. As the firm continues to navigate the complex landscape of global healthcare demands, it remains anchored to its core mission of delivering accessible and affordable healthcare solutions, ensuring that it not only sustains its economic pulse but also positively impacts countless lives worldwide.

ZYDUSLIFE Intrinsic Value
812.98 INR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Zydus Lifesciences Ltd's Deferred Income Tax?
Deferred Income Tax
16.4B INR

Based on the financial report for Sep 30, 2025, Zydus Lifesciences Ltd's Deferred Income Tax amounts to 16.4B INR.

What is Zydus Lifesciences Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
41%

Over the last year, the Deferred Income Tax growth was 271%. The average annual Deferred Income Tax growth rates for Zydus Lifesciences Ltd have been 134% over the past three years , 54% over the past five years , and 41% over the past ten years .

Back to Top